Arcutis Biotherapeutics, Inc. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 58/100
What the filing says
Arcutis reported Q3 2026 net product revenues of $143.9 million (45% YoY growth, 11% sequential), driven by strong ZORYVE demand across all formulations. The company raised full-year 2026 net product sales guidance from $525–540M to $535–545M. Q3 net income was $8.8 million ($0.06–0.07 EPS); cash position stood at $259.8 million; operating cash flow was positive at $18.9 million. Clinical pipeline advances include FDA target date of February 23, 2027 for ZORYVE cream 0.05% in infants, Phase 2 vitiligo results expected by end of 2026, and Phase 2 hidradenitis suppurativa results expected Q1 2027.
Why this rating
Strong revenue growth (+45% YoY) and guidance raise demonstrate execution and market expansion. Guidance increment ~$10M midpoint (~1.8% of $560M midpoint) is modest. For a $1.5B company, a $144M quarterly product line is meaningful but not transformational. Clinical pipeline active but early-stage. Positive operating cash flow supports durability.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.